Covalent inhibitors generally refer to irreversible covalent inhibitors; however, in detailed studies, they can be divided into irreversible covalent inhibitors (ICIs) and reversible covalent inhibitors (RCIs). Advantages of covalent inhibitors […]
CD137/4-1BB combination therapy
In recent years, antibody therapies (including traditional antibodies and nano-antibodies) have become an important means of treating a wide range of human malignant diseases, and more than 100 antibody therapies […]
FDA approved the marketing of 14 drugs in the third quarter of 2023, including 6 small molecule drugs. This article mainly focuses on the drug design ideas of small molecule drugs, hoping […]
With the rise of genomics and proteomics, many clinically significant targets have been discovered in human diseases. However, a relatively small proportion of traditional druggable targets exists, and many targets […]
In 2007, Japanese professors firstly discovered ALK rearrangement and identified the fusion of ALK and EML4 in non-small cell lung cancer specimens. EML4 can promote the activation of ALK kinase […]
CDKs belong to the serine/threonine protein kinase family, and their kinase activity requires binding to cyclins. Abnormalities in CDKs have been reported to cause proliferation, genomic and chromosomal instability that […]
Abstract Immunotherapy has become an indispensable part of cancer treatment. A pivotal phagocytosis checkpoint, named cluster of differentiation 47 (CD47), which functions as a ‘don’t eat me’ signal to protect […]